Article

Society's new name emphasizes sexual medicine

The International Society for Sexual and Impotence Research has changed its name to the International Society for Sexual Medicine. The decision was unanimously approved at the society's recent executive committee meeting.

Related Videos
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Female doctor typing on her laptop computer in medical office | Image Credit: © Rostislav Sedlacek - stock.adobe.com
Study findings highlight gender gaps in oncology authorship and citation
NMIBC Treatment Decisions in the Age of BCG Shortages
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Current Standards of Care and Shifting Strategies in NMIBC
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
1 expert is featured in this series.
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Related Content
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
June 1st 2025

NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC

Benjamin P. Saylor
The findings also lend further credence to the muscle-invasive bladder cancer treatment regimen, investigators reported.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Michiel Van der Heijden, MD, PhD
June 1st 2025

Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC

Benjamin P. Saylor
"The pre-specified thresholds for statistical significance were not met for the dual primary end points of overall survival in cisplatin-ineligible and PD-L1 positive patients," said Michiel Van der Heijden, MD, PhD.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Medically accurate illustration of kidney cancer | Image Credit: © Crystal light - stock.adobe.com
June 1st 2025

Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment

Silas Inman
"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of recurrence," says Naomi B. Haas, MD.
Thomas B. Powles, MBBS, MRCP, MD
May 31st 2025

EFS benefit is seen with sasanlimab in CIS and T1 NMIBC

Benjamin P. Saylor
"There was activity across all the groups from an EFS perspective," said Thomas B. Powles, MBBS, MRCP, MD.
© 2025 MJH Life Sciences

All rights reserved.